ERBB2 and breast cancer: In this cohort study of patients with breast cancer receiving NACT, Black patients had a lower pCR rate for triple-negative and HR−/ERBB2+ breast cancer but a higher pCR rate for HR+/ERBB2− diseases, whereas Asian and Pacific Islander patients had a higher pCR rate for HR−/ERBB2+ diseases.